🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

6+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 6 of 6 recruiting trials for “nut-midline-carcinoma

Phase 2RecruitingNCT07050186

Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma

👨‍⚕️ Jochen H Lorch, MD, Northwestern University📍 1 site📅 Started Aug 2025View details ↗
Phase 2RecruitingNCT06302569

Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma

👨‍⚕️ Giuseppe Procopio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy📍 1 site📅 Started May 2025View details ↗
Phase 2RecruitingNCT06211114

Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma

👨‍⚕️ Xinan Sheng, MD., Peking University Cancer Hospital & Institute📍 2 sites📅 Started Feb 2024View details ↗
Phase 1RecruitingNCT05372640

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

👨‍⚕️ Jia Luo, Dana-Farber - Harvard Cancer Center LAO📍 7 sites📅 Started Aug 2023View details ↗
RecruitingNCT05265429

Biology of Young Lung Cancer Study: The YOUNG LUNG Study

👨‍⚕️ Pasi A Janne, MD, PhD, Dana-Farber Cancer Institute📍 4 sites📅 Started Jan 2023View details ↗
Phase 1, PHASE2RecruitingNCT05019716

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

👨‍⚕️ Jia Luo, Dana-Farber - Harvard Cancer Center LAO📍 5 sites📅 Started Jul 2022View details ↗

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →